New Agreement Puts Itamar Medical Inc. and Arterial Health International on Track to Offer Greater Access to Innovative Cardiovascular Testing in the United States

FRANKLIN, Massachusetts and ATLANTA, April 20, 2015 /PRNewswire/ --

Itamar Medical Inc., a subsidiary of Itamar Medical Ltd. (TASE: ITMR) and Arterial Health International LLC (AHI) announced today they have signed last month a representation agreement.

Under the terms of the agreement, AHI, a leading provider of portable cardiovascular diagnostic solutions to the primary care community, will be Itamar's exclusive cardiovascular diagnostic testing service representative and will market both EndoPAT and WatchPAT to physicians in ten states in the US. AHI will continue to offer EndoPAT testing as a key component of the cardiovascular diagnostic test package it offers to primary care physicians and their patients. In addition, WatchPAT testing will also be added as a part of AHI's suite of services.  As part of the three-year agreement, AHI is also committed to an annual minimum purchase requirement of EndoPAT and WatchPAT devices and accessories from Itamar Medical.

The EndoPAT, manufactured by Itamar Medical, is a device used to test the functioning of the endothelial layer that regulates arterial function. It is the only FDA-cleared device intended for assessing endothelial function, diagnosing coronary artery disease risk and other cardiovascular diseases.

The WatchPAT, manufactured by Itamar Medical, is an FDA cleared Home Sleep Testing device which diagnoses Sleep Apnea, a clinical condition which has been proven to be a substantial risk factor in cardiac diseases.

"We are very excited to continue to build on our long-standing relationship with Itamar and to promote both EndoPAT and WatchPAT as part of our Arterial Health testing. With the addition of WatchPAT for home sleep testing, we will further augment the already comprehensive offerings we carry," said Doug McMillan, CEO of Arterial Health. "We believe our collaboration with Itamar Medical will enable primary care physicians to better address the gaps that currently exist in early detection and prevention of cardiovascular disease."

This agreement marks Itamar Medical's entry into the mobile cardiovascular testing market and builds upon the momentum generated by other international agreements recently signed by the company.

"We recognize an increasing need and demand for arterial function testing, both as a clinical tool for family physicians, and as part of a comprehensive cardiovascular assessment. However, the initial investment to purchase the technology can be an obstacle," said Gilad Glick, CEO of Itamar Medical Ltd. "Our agreement with Arterial Health allows our customers to overcome this financial challenge. It also helps us accelerate penetration into this important market, providing greater access to testing with proven ability to predict cardiac events for the benefit of physicians and patients in the United States."

Itamar Medical Ltd. is a publicly traded medical device company (TASE:ITMR) based in Israel's Caesarea Industrial Park that develops non-invasive medical devices using the proprietary PAT™ (Peripheral Arterial Tone) signal. Since its founding in 1997, the Company has engaged in research and development of non-invasive medical devices for diagnosis of various medical conditions, including cardiovascular disease and respiratory disorders. The first two product lines from Itamar Medical, based on unique technology developed by the Company, are the WatchPAT™ home appliance for respiratory sleep disorder diagnosis, and EndoPAT™, the only device approved by the US. FDA for testing endothelial (arterial) function and assessing the risk of coronary artery disease and other cardiovascular diseases. More information about Itamar Medical can be found online at http://www.itamar-medical.com.

Arterial Health International, LLC®, is based in Atlanta, Georgia, and currently operates in ten US states. The Company supports medical professionals with cutting-edge technology that provides patients with a unique, non-invasive package of clinical diagnostic tests that comprise the most comprehensive evaluation for cardiovascular disease (CVD) risk factors occurring in the arterial system. Learn more about Arterial Health International online at http://www.arterialhealth.net.

For further information:
Shaul Sharoni, Chief Financial Officer, +972-4-617000, [email protected]
Eran Gabay, Gelbart-Kahana Investor Relations, +972-54-2467378, [email protected]

SOURCE Itamar Medical Inc.